The Lizard Isn’t Hungry, Is It?

In this first quarter of the 21st century, cancer and diabetes have been major research priorities. And who would have thought that one of the most interesting drugs of our time would be discovered from a desert lizard? This is the story of GLP-1 medications—drugs originally developed for diabetes that became a revolution in weight loss treatment.

In the early 1990s, Dr. John Eng at the Veterans Administration Medical Center in the Bronx was studying the Gila monster (Heloderma suspectum), a venomous lizard native to the southwestern United States. What intrigued Dr. Eng was the lizard’s remarkable metabolic adaptation—despite eating only 3-4 times per year, it maintained stable blood sugar levels.

Through painstaking research, Dr. Eng isolated a peptide from the lizard’s venom that he named exendin-4. This compound shared approximately 53% sequence identity with human GLP-1 (Glucagon-Like Peptide-1) but had a crucial advantage: while human GLP-1 has a half-life of only 2 minutes in the body, exendin-4 remained active for hours.

From Diabetes Drug to Weight Loss Sensation

When exenatide (Byetta) first received FDA approval in 2005, it was marketed exclusively as a diabetes medication. The primary goal was blood sugar control, but doctors and patients quickly noticed something unexpected: significant weight loss in many users.

This “side effect” transformed the pharmaceutical landscape. By 2014, liraglutide received FDA approval specifically for weight management under the brand name Saxenda. Then came semaglutide (Wegovy) in 2021, showing even more dramatic weight loss results.

The shift from diabetes treatment to obesity management represents one of the most significant pivots in modern pharmaceutical history:

The Original Intent: Diabetes Control

  • HbA1c reductions of 1.0-2.0%
  • Glucose-dependent insulin secretion
  • Prevention of hypoglycemia

The Unexpected Discovery: Weight Loss

  • Liraglutide: 5-8% body weight reduction
  • Semaglutide: 15-17% body weight reduction
  • Tirzepatide: 15-20% body weight reduction

These results approach bariatric surgery effectiveness without invasive procedures.

The Science Behind GLP-1

GLP-1 is an incretin hormone—a gut hormone that stimulates insulin secretion in response to food intake. But its effects go far beyond blood sugar control:

Pancreatic Effects

  • Stimulates insulin secretion only when blood glucose is elevated
  • Inhibits glucagon release from pancreatic α-cells
  • Preserves β-cell function over time

Central Nervous System Effects (Key for Weight Loss)

  • Activates satiety centers in the brain
  • Reduces food reward signaling
  • Decreases appetite and caloric intake

Gastrointestinal Effects

  • Slows gastric emptying
  • Reduces intestinal motility
  • Enhances feelings of fullness

Cardiovascular Effects

  • Improves endothelial function
  • Reduces blood pressure
  • Provides direct cardioprotection

Where is that miracle pill?

The development of oral GLP-1 medications represents a crucial next step. Rybelsus (oral semaglutide) became the first FDA-approved oral GLP-1 in 2019, though it’s currently only approved for diabetes. An oral form specifically for weight loss could dramatically expand access and improve adherence.

Challenges in developing oral GLP-1s include:

  • Peptides are typically broken down in the stomach
  • Poor absorption through intestinal walls
  • Maintaining stable blood levels
  • Achieving comparable efficacy to injections

Current Challenges and Future Directions

Despite their success, GLP-1 medications face several hurdles:

Immediate Challenges

  • Cost: Monthly prices often exceed $1,000
  • Access: Insurance rarely covers weight loss indications
  • Supply: Manufacturing struggles to meet exploding demand
  • Side effects: Gastrointestinal symptoms affect 30-50% of users

Future Developments

  • Oral formulations: Expanding beyond current limited options
  • Combination therapies: Multi-receptor agonists for enhanced efficacy
  • New indications: NASH, Alzheimer’s, addiction treatment
  • Next-generation molecules: Improved tolerability and convenience

Keeping Our Lizard Slim

The journey from Gila monster venom to weight loss revolution demonstrates how medical breakthroughs often come from unexpected places. What began as diabetes research evolved into one of the most effective obesity treatments ever developed.

Just as the Gila monster maintains its slim profile through metabolic efficiency, these medications help humans achieve similar results. But unlike the lizard’s twice-yearly injection of venom, humans currently need weekly or daily injections—a limitation that oral formulations could soon overcome.

The future of GLP-1 medications looks promising, with potential applications extending far beyond weight loss and diabetes. As research continues and delivery methods improve, the lizard’s secret might become accessible to millions more people worldwide.

References

Athauda, D., Maclagan, K., Skene, S. S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., Li, Y., Aviles-Olmos, I., Warner, T. T., Limousin, P., Lees, A. J., Greig, N. H., Tebbs, S., & Foltynie, T. (2017). Exenatide once weekly versus placebo in Parkinson’s disease: A randomised, double-blind, placebo-controlled trial. The Lancet, 390(10103), 1664-1675.

Chen, Y. S., Wang, C. H., Zhang, C., Wang, X. L., & Zhang, Q. (2004). Expression and purification of exendin-4, a GLP-1 receptor agonist, in Escherichia coli. Protein Expression and Purification, 38(2), 292-299.

Davies, M. J., et al. (2023). Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity. Diabetes Care, 47(11), 1873-1892.

Department of Veterans Affairs. (2021). Diabetes drug from Gila monster venom. VA Research in Action. https://www.research.va.gov/research_in_action/Diabetes-drug-from-Gila-monster-venom.cfm

Drucker, D. J. (2018). Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metabolism, 27(4), 740-756.

Eli Lilly. (2010). History of exenatide. Investor Relations News Archive.

Eng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992). Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Journal of Biological Chemistry, 267(11), 7402-7405.

FDA. (2023). FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. https://www.fda.gov/drugs/drug-safety-and-availability/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize

Frias, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385, 503-515.

Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., Xavier, D., Atisso, C. M., Dyal, L., Hall, S., Rao-Melacini, P., Wong, G., Avezum, A., Basile, J., Chung, N., … & REWIND Investigators. (2019). Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial. The Lancet, 394(10193), 121-130.

Gomes, C. L., Romero, C., & Sardesi, S. (2022). Public interest in the off-label use of glucagon-like peptide 1 agonists (Ozempic) for cosmetic weight loss: A Google trends analysis. Aesthetic Surgery Journal, 44(4), NP279-NP286.

Grieco, M., Giorgi, A., Gentile, M. C., d’Erme, M., Morano, S., Maras, B., & Filardi, T. (2019). Glucagon-like peptide-1: Antioxidant effects and signaling pathways. International Journal of Molecular Sciences, 20(13), 3331.

Habener, J. F., Drucker, D. J., Mojsov, S., Knepel, W., & Philippe, J. (1983). Biosynthesis of glucagon. In P. J. Lefebvre (Ed.), Glucagon I (pp. 53-71). Springer.

Holst, J. J. (2023). The many actions of GLP-1 on metabolism. Nature Reviews Molecular Cell Biology, 24, 409–422.

Kaiser Family Foundation. (2023). Costly GLP-1 drugs are rarely covered for weight loss by marketplace plans. https://www.kff.org/affordable-care-act/press-release/costly-glp-1-drugs-are-rarely-covered-for-weight-loss-by-marketplace-plans/

Knudsen, L. B., Nielsen, P. F., Huusfeldt, P. O., Johansen, N. L., Madsen, K., Pedersen, F. Z., Thøgersen, H., Wilken, M., & Agersø, H. (2019). The discovery and development of liraglutide and semaglutide. Frontiers in Endocrinology, 10, 155.

Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. (2020). Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials. The Lancet Diabetes & Endocrinology, 7(10), 776-785.

Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., Steinberg, W. M., Stockner, M., Zinman, B., Bergenstal, R. M., Buse, J. B., LEADER Steering Committee, & LEADER Trial Investigators. (2016). Liraglutide and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 375(4), 311-322.

Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., Woo, V., Hansen, O., Holst, A. G., Pettersson, J., Vilsbøll, T., & SUSTAIN-6 Investigators. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 375(19), 1834-1844.

Mojsov, S., Weir, G. C., & Habener, J. F. (1987). Insulinotropin: Glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. Journal of Clinical Investigation, 79(2), 616-619.

Müller, T. D., Finan, B., Bloom, S. R., D’Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., Holst, J. J., Langhans, W., Meier, J. J., Nauck, M. A., Perez-Tilve, D., Pocai, A., Reimann, F., Sandoval, D. A., Schwartz, T. W., … & Tschöp, M. H. (2019). Glucagon-like peptide 1 (GLP-1). Molecular Metabolism, 30, 72-130.

National Institute on Aging. (2018). Exendin-4: From lizard to laboratory…and beyond. https://www.nia.nih.gov/news/exendin-4-lizard-laboratory-and-beyond

Nauck, M. A., & Meier, J. J. (2018). Incretin hormones: Their role in health and disease. Diabetes, Obesity and Metabolism, 20(Suppl 1), 5-21.

Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., Harrison, S. A., & NN9931-4296 Investigators. (2021). A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. New England Journal of Medicine, 384(12), 1113-1124.

Novo Nordisk. (2023). Novo Nordisk announces headline results from the FLOW trial with oral semaglutide in people with type 2 diabetes and chronic kidney disease. Company Announcement. https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=164155

Rosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): A double-blind, randomised, phase 3 trial. The Lancet, 398(10295), 143-155.

Tak, Y. J., & Lee, S. Y. (2021). Emerging role of GLP-1 agonists in obesity: A comprehensive review of randomised controlled trials. International Journal of Molecular Sciences, 22(13), 10449.

Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine, 389(10), 930-942.